Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral medication
|
| gptkbp:alsoKnownAs |
tegafur/gimeracil/oteracil
|
| gptkbp:approvedBy |
gptkb:Japan
several Asian countries |
| gptkbp:ATCCode |
L01BC53
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:Japan
|
| gptkbp:gimeracilFunction |
inhibits dihydropyrimidine dehydrogenase
|
| gptkbp:hasComponent |
gptkb:tegafur
gptkb:gimeracil gptkb:oteracil |
| https://www.w3.org/2000/01/rdf-schema#label |
S-1
|
| gptkbp:marketedAs |
gptkb:Taiho_Pharmaceutical
|
| gptkbp:mechanismOfAction |
antineoplastic agent
|
| gptkbp:oteracilFunction |
reduces gastrointestinal toxicity
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hand-foot_syndrome
nausea vomiting diarrhea anorexia fatigue mucositis myelosuppression |
| gptkbp:tegafurIs |
prodrug of 5-fluorouracil
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
gptkb:cancer colorectal cancer pancreatic cancer gastric cancer |
| gptkbp:bfsParent |
gptkb:Stalinets-class
|
| gptkbp:bfsLayer |
6
|